NCT03760523View on ClinicalTrials.gov

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 18, 2019

Primary Completion Date

October 9, 2023

Study Completion Date

October 9, 2023

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Minnelide

Patients will take Minnelide orally once daily on Days 1-21 of 28 day Cycle. Dose Escalation Schedule: Dose Level -1: .5 mg, Dose Level 1: .75 mg, Dose Level 2: 1 mg, Dose Level 3: 1.25 mg.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors
All Listed Sponsors
collaborator

Minneamrita Therapeutics LLC

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT03760523 - Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter